Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Nexgel (NXGLW) Research & Development (2021 - 2025)

Nexgel's Research & Development history spans 5 years, with the latest figure at -$6000.0 for Q4 2025.

  • For Q4 2025, Research & Development changed N/A year-over-year to -$6000.0; the TTM value through Dec 2025 reached $2000.0, down 97.44%, while the annual FY2025 figure was $2000.0, 97.44% down from the prior year.
  • Research & Development reached -$6000.0 in Q4 2025 per NXGLW's latest filing, down from $7000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $193000.0 in Q3 2022 to a low of -$6000.0 in Q4 2025.
  • Average Research & Development over 5 years is $36312.5, with a median of $13500.0 recorded in 2021.
  • Peak YoY movement for Research & Development: surged 1010.0% in 2022, then tumbled 96.89% in 2023.
  • A 5-year view of Research & Development shows it stood at $14000.0 in 2021, then skyrocketed by 178.57% to $39000.0 in 2022, then crashed by 66.67% to $13000.0 in 2023, then soared by 484.62% to $76000.0 in 2024, then crashed by 107.89% to -$6000.0 in 2025.
  • Per Business Quant, the three most recent readings for NXGLW's Research & Development are -$6000.0 (Q4 2025), $7000.0 (Q3 2025), and $1000.0 (Q1 2025).